CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Iovance Biotherapeutics, Inc. (IOVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Iovance Biotherapeutics, Inc. (IOVA)

Biological Products, (No Diagnostic Substances) · market cap $4.7B · as of 2026-08-14

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-04-30 (est.)
Phase 2
Pipeline
12
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Iovance Biotherapeutics is a commercial-stage cell therapy company built around tumor-infiltrating lymphocyte (TIL) therapy, with lead product Amtagvi (lifileucel) already on the market for advanced melanoma and a Phase 3 confirmatory/label-expansion program combining lifileucel with pembrolizumab. FY2025 revenue reached $264M (up from $164M in 2024), but the company remains deeply unprofitable (-$391M net) and is running with only ~8 months of cash at $196.5M — the central tension in the story.
The catalyst path
  • 2027-04-30 (est.)Phase 2 · Aldesleukinimp 7/10
  • 2027-09-15 (est.)Phase 2 · IOV-4001imp 7/10
Pipeline
AssetPhaseIndication
LN-145Phase 2Metastatic Non Small Cell Lung Cancer
IOV-3001Phase 2Unresectable Melanoma
IOV-2001Phase 2Chronic Lymphocytic Leukemia
LN-145-S1Phase 2Squamous Cell Carcinoma of the Head and Neck
Lifileucel plus PembrolizumabPhase 3Metastatic Melanoma
LifileucelPhase 2Endometrial Cancer
IOV-4001Phase 2Unresectable Melanoma
Autologous Tumor Infiltrating Lymphocytes LN-145Phase 2Bone Sarcoma
E7 TCR-T cellsPhase 2Cervical Cancer
AldesleukinPhase 2HPV-Associated Cervical Carcinoma
Tumor infiltrating lymphocytes (TIL) LN-145Phase 2Metastatic Triple Negative Breast Cancer
Autologous Tumor Infiltrating Lymphocytes LN-145-S1Phase 2Bone Sarcoma
Price & technical context
3-month
+40.1%
6-month
+112.7%
12-month
+346.2%
52-wk range
$1.81–$14.86
vs 50-day MA
-23.6%
vs 200-day MA
+46.7%
Realized vol
108.4%
Max drawdown
-86.5%

Daily closes through 2026-11-04. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IOVA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.